To boost its portfolio in inflammatory and immunological therapeutics, AbbVie has agreed to acquire Apogee Therapeutics, a Waltham, Massachusetts-based clinical-stage bio/pharmaceutical company, for $10.9 billion. 

Apogee’s lead assets are zumilokibart, a subcutaneous half-life extended monoclonal antibody for treating atopic dermatitis (eczema) in Phase II development, and APG273, a combination of zumilokibart and APG333, an antibody that blocks thymic stromal lymphopoietin, a signaling protein that acts as an early trigger of inflammation in the lungs. APG273 is in Phase I development for treating asthma. Zumilokibart targets IL-13, a critical cytokine in Type 2 inflammation in diseases such as atopic dermatitis and asthma. Beyond zumilokibart, Apogee has a broader pipeline of antibodies targeting multiple validated inflammatory pathways. 

Under the agreement, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash for a total equity value of approximately $10.9 billion. The Boards of Directors of both companies have unanimously approved the transaction. This transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals. 

Source: AbbVie